Cordycepin, the compound the marketing rests on, is taken apart by an enzyme your body already makes, leaving it a short half-life and low bioavailability.
The pharmacology paper is a review and reports no human half-life figure. Its interest is in engineering cordycepin into something usable, with an enzyme inhibitor, a redesigned molecule or a new delivery system, none of which exists in a capsule. And it never asks the separate question of whether the amounts in a supplement would matter even if they did survive.